We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.